E-Cadherin and EpCAM expression by NSCLC tumour cells associate with normal fibroblast activation through a pathway initiated by integrin αvβ6 and maintained through TGFβ signalling

Oncogene

Volumn 34, Issue 6, 2015, Pages 704-716

  Eberlein, C ^a   Rooney, C ^a   Ross, S J ^a   Farren, M ^a   Weir, H M ^a   Barry, S T ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

CAF; integrin; NSCLC; stroma; TGF ; v 6

Indexed keywords

AFATINIB; ALPHAVBETA6 INTEGRIN; AZD 8931; CADHERIN; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; INTEGRIN; QUINAZOLINE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; TUMOR PROTEIN;

BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; COCULTURE; DRUG EFFECTS; FIBROBLAST; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; STROMA CELL;

ANTIGENS, NEOPLASM; CADHERINS; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION MOLECULES; COCULTURE TECHNIQUES; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRINS; NEOPLASM PROTEINS; QUINAZOLINES; SIGNAL TRANSDUCTION; STROMAL CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 85028196338     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.600     Document Type: Article

References (47)

1. Yazhou C, Wenlv S, Weidong Z, Licun W. Clinicopathological significance of stromal myofibroblasts in invasive ductal carcinoma of the breast. Tumour Biol 2004; 25: 290-295.
2. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V et al. A stromarelated gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009; 15: 68-74.
3. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008; 14: 5198-5208.
4. Maeshima AM, Niki T, Maeshima A, Yamada T, Kondo H, Matsuno Y. Modified scar grade: a prognostic indicator in small peripheral lung adenocarcinoma. Cancer 2002; 95: 2546-2554.
5. Cardone A, Tolino A, Zarcone R, Borruto Caracciolo G, Tartaglia E. Prognostic value of desmoplastic reaction and lymphocytic infiltration in the management of breast cancer. Panminerva Med 1997; 39: 174-177.
6. Surowiak P, Suchocki S, Györffy B, Gansukh T, Wojnar A, Maciejczyk A et al. Stromal myofibroblasts in breast cancer: relations between their occurrence, tumour grade and expression of some tumour markers. Folia Histochem Cytobiol 2006; 44: 111-116.
7. Mink SR, Vashistha S, Zhang W, Hodge A, Agus DB, Jain A. Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumours reverse EGFR pathway inhibition by EGFR-TKIs. Mol Cancer Res 2010; 8: 809-820.
8. Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB et al. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest 2011; 121: 1313-1328.
9. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012; 487: 500-504.
10. Ronnov-Jessen L, Petersen OW, Bissell MJ. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 1996; 76: 69-125.
11. Bremnes RM, Dønnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R et al. The role of tumour stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol 2011; 6: 209-217.
12. Egeblad M, Nakasone ES, Werb Z. Tumours as organs: complex tissues that interface with the entire organism. Dev Cell 2010; 18: 884-901.
13. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
14. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 239-252.
15. Ronnov-Jessen L, Petersen OW. Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab Invest 1993; 68: 696-707.
16. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401.
17. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumour growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-348.
18. Navab R, Strumpf D, Bandarchi B, Zhu CQ, Pintilie M, Ramnarine VR et al. Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc Natl Acad Sci USA 2011; 108: 7160-7165.
19. Marsh D, Suchak K, Moutasim KA, Vallath S, Hopper C, Jerjes W et al. Stromal features are predictive of disease mortality in oral cancer patients. J Pathol 2011; 223: 470-481.
20. Brentnall TA, Lai LA, Coleman J, Bronner MP, Pan S, Chen R. Arousal of cancerassociated stroma: overexpression of palladin activates fibroblasts to promote tumour invasion. PLoS One 2012; 7: e30219.
21. Rasanen K, Vaheri A. Activation of fibroblasts in cancer stroma. Exp Cell Res 2010; 316: 2713-2722.
22. Eberlein C, Kendrew J, McDaid K, Alfred A, Kang JS, Jacobs VN et al. A human monoclonal antibody 264RAD targeting alphavbeta6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo. Oncogene 2013; 32: 4406-4416.
23. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999; 96: 319-328.
24. Aluwihare P, Mu Z, Zhao Z, Yu D, Weinreb PH, Horan GS et al. Mice that lack activity of alphavbeta6-and alphavbeta8-integrins reproduce the abnormalities of Tgfb1-and Tgfb3-null mice. J Cell Sci 2009; 122: 227-232.
25. Lewis MP, Lygoe KA, Nystrom ML, Anderson WP, Speight PM, Marshall JF et al. Tumour-derived TGF-beta1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells. Br J Cancer 2004; 90: 822-832.
26. Varga J. Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosis. Arthritis Rheum 2002; 46: 1703-1713.
27. Schiller M, Javelaud D, Mauviel A. TGF-beta-induced SMAD signaling and gene regulation: consequences for extracellular matrix remodeling and wound healing. J Dermatol Sci 2004; 35: 83-92.
28. Ross S, Hill CS. How the Smads regulate transcription. Int J Biochem Cell Biol 2008; 40: 383-408.
29. Zieba A, Pardali K, Söderberg O, Lindbom L, Nyström E, Moustakas A et al. Intercellular variation in signaling through the TGF-beta pathway and its relation to cell density and cell cycle phase. Mol Cell Proteomics 2012; 11: M111.013482.
30. Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002; 62: 65-74.
31. Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, Ben-Porath I et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumour-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci USA 2010; 107: 20009-20014.
32. McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S et al. Tumour cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med 2010; 16: 483-489.
33. Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 2007; 13: 1576-1583.
34. Hickinson DM, Klinowska T, Speake G, Vincent J, Trigwell C, Anderton J et al. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin Cancer Res 2010; 16: 1159-1169.
35. Minkovsky N, Berezov A. BIBW-2992 a dual receptor tyrosine kinase inhibitor for the treatment of solid tumours. Curr Opin Investig Drugs 2008; 9: 1336-1346.
36. Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G et al. The identification of 2-(1 H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008; 51: 5522-5532.
37. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012; 21: 418-429.
38. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324: 1457-1461.
39. Kano MR, Bae Y, Iwata C, Morishita Y, Yashiro M, Oka M et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumours by inhibition of TGF-beta signaling. Proc Natl Acad Sci USA 2007; 104: 3460-3465.
40. Puthawala K, Hadjiangelis N, Jacoby SC, Bayongan E, Zhao Z, Yang Z et al. Inhibition of integrin alpha(v)beta6, an activator of latent transforming growth factorbeta, prevents radiation-induced lung fibrosis. Am J Respir Crit Care Med 2008; 177: 82-90.
41. Horan GS, Wood S, Ona V, Li DJ, Lukashev ME, Weinreb PH et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med 2008; 177: 56-65.
42. Popov Y, Patsenker E, Stickel F, Zaks J, Bhaskar KR, Niedobitek G et al. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol 2008; 48: 453-464.
43. Marsh D, Dickinson S, Neill GW, Marshall JF, Hart IR, Thomas GJ. alpha vbeta 6 Integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation. Cancer Res 2008; 68: 3295-3303.
44. Thomas GJ, Lewis MP, Whawell SA, Russell A, Sheppard D, Hart IR et al. Expression of the alphavbeta6 integrin promotes migration and invasion in squamous carcinoma cells. J Invest Dermatol 2001; 117: 67-73.
45. Gaggioli C, Hooper S, Hidalgo-Carcedo C, Grosse R, Marshall JF, Harrington K et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol 2007; 9: 1392-1400.
46. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N et al. A gene expression signature associated with 'K-Ras addiction' reveals regulators of EMT and tumour cell survival. Cancer Cell 2009; 15: 489-500.
47. Lebret SC, Newgreen DF, Thompson EW, Ackland ML. Induction of epithelial to mesenchymal transition in PMC42-LA human breast carcinoma cells by carcinoma-associated fibroblast secreted factors. Breast Cancer Res 2007; 9: R19.